Adalimumab Injection (Sulinnuo® by Xinda Biopharma) 40?mg Prefilled Syringe

Adalimumab Injection (Sulinnuo® by Xinda Biopharma) 40?mg Prefilled Syringe

(1 条用户评价)

$1.00

Adalimumab Injection (Sulinnuo®), 40?mg/0.8?ml prefilled syringe, produced by Xinda Biopharma (Suzhou). NMPA-approved under S20200020. A high-quality biosimilar anti?TNF?? agent for inflammation and autoimmune research. Wholesale and retail supported.

EMI starting from $0.00/month - View Plans
Compare

描述

Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor?? (TNF??), a key cytokine in inflammatory and autoimmune pathways. Sulinnuo® is Xinda Biopharma’s domestically produced biosimilar equivalent to Humira®, supplied in a 40?mg/0.8?ml prefilled syringe format for precise dosing.

The product is manufactured by Xinda Biopharma (Suzhou) and received Chinese NMPA approval S20200020. It is commonly utilized in research projects modeling rheumatoid arthritis, Crohn’s disease, psoriasis, and other TNF-mediated inflammation processes.

?? For laboratory research use only. Not intended for clinical, veterinary, or diagnostic use.


Adalimumab Injection Product Specifications

Parameter Details
Product Name Adalimumab Injection (Sulinnuo®)
Generic Name Adalimumab
Mab Type Fully human anti?TNF?? IgG1 monoclonal antibody
Formulation Prefilled syringe (subcutaneous injection)
Strength 40?mg in 0.8?ml
Packaging One syringe per box
Approval Number S20200020 (NMPA)
Manufacturer Xinda Biopharma (Suzhou), China
Intended Use Laboratory research only
Storage Conditions Store refrigerated at 2–8?°C; protect from light

Adalimumab Injection Mechanism & Research Applications

Adalimumab selectively binds TNF??, neutralizing its pro-inflammatory effects and preventing receptor activation. Sulinnuo® is employed in research for:

  • Autoimmune disease models (RA, Crohn’s, psoriasis, uveitis)

  • Inflammatory signaling and cytokine cascade studies

  • Comparative efficacy of biosimilars vs originators

  • Preclinical evaluation of TNF?? blockade mechanisms


Adalimumab Injection Side Effects (Observed in Preclinical/Research Settings)

Based on clinical biosimilar data, research models may show:

  • Increased susceptibility to infections (e.g. TB, fungal, bacterial)

  • Infusion or injection site reactions (fever, chills, hypotension)

  • Laboratory anomalies: elevated liver enzymes, cytopenias

  • Autoimmune phenomena akin to lupus-like syndrome

  • Rare risks: demyelinating events, lymphoma (high-dose/prolonged exposure)

Recommendation: Monitor immunological markers and animal health.


Safety & Handling

  • Use Restriction: For laboratory research only

  • PPE: Use gloves, lab coat, and safety eyewear

  • Storage: Store at 2–8?°C, avoid freezing or direct light

  • Preparation: Use aseptic technique during handling

  • Disposal: Follow institutional biohazard guidelines


Core Keywords

Adalimumab Sulinnuo injection, Xinda Biopharma adalimumab, 40?mg prefilled TNF?? antibody, S20200020 biosimilar adalimumab, lab-grade adalimumab syringe, autoimmune research biologic, wholesale adalimumab, TNF?? inhibitor for research


Research Use Disclaimer

This product is exclusively for laboratory research. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. Misuse may result in health risks and regulatory penalties. Users must follow biosafety and chemical handling protocols as per institutional guidelines.

其他信息

重量 1 公斤
尺寸 26 × 23 × 26 厘米

Adalimumab Injection (Sulinnuo® by Xinda Biopharma) 40?mg Prefilled Syringe 有 1 个评价

  1. glenv

    Received, it takes 12 days to ship from China

添加评价

您的邮箱地址不会被公开。 必填项已用 * 标注

EMI Options

Select at least 2 products
to compare